The company's mission is to advance the treatment of poorly understood human diseases with an underlying immune component by harnessing the power of the human immune system. AbVitro discovers and evaluates fully human antibody binders for therapeutic potential while simultaneously uncovering new potential therapeutic targets or biomarkers. They achieve this by using Next Generation Sequencing (NGS) and single-cell in emulsion based technologies to gain insights into the biology that underlies physiological and pathological adaptive immune responses.